Evaluation of liver function during administration of nifenazone in rheumatic disease on the basis of serum protein studies and enzyme tests.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000591:Amino Acid Isomerases / Q000097:blood; D000983:Antipyrine / Q000008:administration & dosage / Q000627:therapeutic use*; D001798:Blood Proteins / Q000032:analysis*; D004796:Clinical Enzyme Tests; D004305:Dose-Response Relationship, Drug; D005260:Female; D005956:Glucose-6-Phosphate Isomerase / Q000097:blood; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology
D001798:Blood Proteins; D009536:Niacinamide; D000591:Amino Acid Isomerases; D005956:Glucose-6-Phosphate Isomerase; D000983:Antipyrine